Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers O > Headlines for Opexa Therapeutics, Inc. > News item |
Opexa Therapeutics files $35 million stock, debt, preferreds shelf
By Devika Patel
Knoxville, Tenn., Nov. 18 - Opexa Therapeutics Inc. filed a $35 million shelf registration in an S-3 filing with the Securities and Exchange Commission.
The registration covers common stock, preferred stock, debt securities, depositary shares and warrants.
The securities may be structured as convertibles.
Proceeds will be used for general corporate purposes.
The Woodlands, Texas-based Opexa develops and commercializes cell therapies to treat autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and diabetes.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.